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Introduction: Metastasectomy is hypothesised to improve OS in metastatic STS, but evidence in favour of
this approach derives from non-controlled single-arm cohorts affected by selection bias. The objective
was to quantify the effect of metastasectomy vs. non-surgical management on overall survival (OS) in
patients with metachronous metastases from extremity- and trunk soft tissue sarcoma (STS).
Materials and methods: From a population of 1578 STS patients, 135 patients who underwent surgery for
localised STS at two European centres between 1998 and 2015 and developed metachronous STS me-
tastases were included. Propensity score analyses with inverse-probability-of-treatment-weights (IPTW)
and landmark analyses were performed to control for selection and immortal time bias, respectively.
Results: OS was significantly longer in the 68 patients undergoing metastasectomy than in the 67 pa-
tients who were treated non-invasively for their metastasis (10-year OS: 23% vs. 4%; hazard ratio
(HR) ¼ 0.34, 95% CI: 0.22e0.53, p < 0.0001). This association prevailed after IPTW-weighting of the data
to control for the higher prevalence of favourable prognostic factors in the surgery group (adjusted 10-
year OS: 17% vs. 3%, log-rank p < 0.0001; HR ¼ 0.33, 95% CI: 0.20e0.52, p < 0.0001). Five-year OS es-
timates were 27.8% in patients who had and 14.5% in patients who had not undergone metastasectomy
within the first 3 months after diagnosis of a metastasis (p < 0.0001).
Conclusion: In this observational bi-centre study, metastasectomy was associated with prolonged sur-
vival in patients with metachronous STS metastases. In the absence of randomized studies, our results
indicate that metastasectomy should be considered as an important treatment option for metachronous
STS metastases.
© 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.cs and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.
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Soft tissue sarcomas (STS) constitute a group of rare mesen-
chymal tumours with diverse molecular, histologic, and clinical
features [1]. While a significant number of patients with localised
STS can be cured with wide surgical resection, up to a third of pa-
tients will develop metachronous distant metastases [2]. Patients
withmetastatic STS have limited systemic treatment options and in
general a poor prognosis, with median survival averaging one year
[3,4].
Although chemotherapy is considered the standard treatment
for advanced STS [5], metastasectomy represents an emerging
practise in this patient population [5]. Evidence in favour of a sur-
gical approach in the metastatic setting comes from several large
retrospective case series investigating overall survival (OS) out-
comes of patients who had undergone (mostly pulmonary) meta-
stasectomy [6e23]. These studies have shown very encouraging
survival outcomes, far beyond the expected average median sur-
vival of around 1 year for metastatic STS. Furthermore, cases with
long-term remissions or even potential cure after complete surgical
excision of STS metastases have been reported in this context [24].
However, as current studies on metastasectomy in STS are not only
retrospective in their nature but also uncontrolled for biases, the
question whether metastasectomy improves outcomes as
compared to a purely “non-invasive” approach with chemotherapy
and supportive measures is currently unknown [25]. Indeed, most
evidence on metastasectomy comes from single-centre cohorts
within highly specialised tertiary centres involving patients that
were likely selected for potentially favourable prognostic factors
such as a good performance status, a long metachronous interval,
resectable lesions, and/or low metastatic tumour load. Thus,
whether favourable outcomes in these cohorts were due to meta-
stasectomy or rather due to the selection of patients with a
favourable prognosis for metastasectomy is unclear [25].
While a randomized controlled trial of metastasectomy versus
non-invasive treatment would be optimal for quantifying the
benefit of surgery in this setting, data from such a trial are un-
available at present, and unlikely to become available in the future
due to ethical and logistical reasons [26,27]. In the absence of
randomized data, comparative effectiveness studies of observa-
tional data may provide guidance for surgeons, medical oncologists
and patients [28]. In this study, we perform a comparative effec-
tiveness analysis of surgery versus “non-surgery in patients with
metachronous metastases of STS using propensity-score analysis
and Inverse Probability of Treatment Weight (IPTW)-modelling.
However, even this controlled study is subject to potential selection
bias, because treatment assignment to surgery is non-random. A
naïve analysis of such data may lead to an overestimation of the
potential benefit of metastasectomy. To overcome this limitation,




In this bi-centre historical cohort study, we retrospectively
included 135 patients who were diagnosed with metachronous
metastases from histologically-confirmed extremity and trunk STS
at two European tertiary centres (Medical University of Graz:
n ¼ 87, Leiden University Medical Centre: n ¼ 48). All 135 patients
had previously undergone surgerywith curative intent for localised
STS at these centres, and were drawn from the greater population
of 517 patients who had undergone surgery for localised STS be-
tween 1998 and 2017 at the Medical University of Graz and 1030Please cite this article in press as: Smolle MA, et al., Surgery for metach
analysis using propensity score methods, European Journal of Surgical Ocorresponding patients treated between 2000 and 2015 at the
Leiden University Medical Centre. Patients with a short follow-up
or missing essential information were excluded (Supplementary
Figure 1). Two patients initially diagnosed with grade 1 STS were
likewise included, as they were subsequently upgraded (Table 1).
Demographic variables and tumour- and treatment-related
factors e with special focus on management of metastatic disease
e were documented retrospectively as previously described
[31,32]. Eastern Cooperative Oncology Group (ECOG) status, as well
as haemoglobin and albumin levels, were determined for each
patient, as documented at the latest Tumour Board Meeting (TBM)
prior to treatment of the metastases.
Date of diagnosis of disseminated disease was defined as the
first clinical appointment where imaging studies (i.e. computed
tomography, magnetic resonance imaging, chest X-ray, positron-
emission tomography) provided an indication for metastatic
spread that was consecutively confirmed by further metastatic
spread, progressive disease or histological examination of resected
metastatic nodules. Two study groups were defined retrospectively
based on their treatment post diagnosis of metastases: (1) Patients
who had undergone any surgical intervention, and (2) patients who
had not undergone any surgical intervention. Both groups included
patients that received non-invasive treatment approaches, such as
chemotherapy or palliative radiotherapy. Treatments were indi-
cated by the multi-disciplinary TBM. Follow-up was calculated
from the date of diagnosis of disseminated disease (“baseline date”)
until death or end of records. Primary endpoint of this study was
OS.
Statistical methods
All statistical analyses were performed using Stata (Windows
version 14.0, Stata Corp., Houston, TX, USA). Standardized mean
differences (SMDs) were used to quantify differences in means
and proportions of variables between the two study groups
(surgical intervention vs. no surgical intervention), with SMDs 
0.3 being considered indicative of a relevant between-group
imbalance. Median follow-up was computed according to the
method of Schemper and Smith [29], and OS with a Kaplan-Meier
estimator. For comparison of survivor functions between the two
study groups, we used log-rank tests. To investigate the associa-
tion of risk factors with survival, uni- and multivariable Cox
models were estimated. The proportionality of hazard assumption
was evaluated by fitting an interaction between a variable of in-
terest and linear follow-up time. The propensity score was
defined as the probability of undergoing surgical intervention
conditional on baseline covariates [30]. This propensity score was
predicted from a multivariable logistic regression model (all
included covariates are reported in Supplementary Table 1 and
are based on clinical experience as well as literature [4,33,34]).
For this propensity score model, missing baseline covariates were
imputed with a chained equations algorithm with 10 imputation
datasets (list with conditional imputation models available from
FP upon request). The inverse-probability-of-treatment-weight
(IPTW) was then defined as the inverse of the probability of
receiving the treatment that the patient received (also known as
the “average treatment effect on the treated”). Following best
practise recommendations, SMDs were recalculated after weigh-
ing of the data with the IPTWs as a method of balance diagnostics
[30]. Here, we pre-specified that the IPTW achieved sufficient
balance if an unadjusted SMD  0.3 was lowered below this
threshold. The primary endpoint of the analysis, i.e. the associa-
tion between treatment assignment and OS, was then studied
with a univariable Cox model which was weighted for the IPTW,
as well as IPTW-weighted Kaplan-Meier estimators and log-rankronous metastasis of soft tissue sarcoma e A magnitude of benefit
ncology (2018), https://doi.org/10.1016/j.ejso.2018.06.019
Table 1
Baseline characteristics of the study population. Distribution overall and by treatment group.
n (% missing) Overall (n ¼ 135) No surgical intervention (n ¼ 67) Surgical intervention (n ¼ 68) p-value SMD SMD-IPTW
Gender
Male 135 (0%) 80 (59%) 43 (64%) 37 (54%) 0.248 0.20 0.09
Female 55 (41%) 24 (36%) 31 (46)
Location of Primary Tumour
Upper limb 135 (0%) 37 (27%) 21 (31%) 16 (24%) 0.510 0.17 0.01
Lower limb 90 (67%) 43 (64%) 47 (69%) 0.10 0.03
Trunk 8 (6%) 3 (4%) 5 (7%) n/a n/a
Histology of Primary Tumour
Angiosarcoma 135 (0%) 6 (4%) 4 (6%) 2 (3%) 0.557 n/a n/a
MPNST 13 (10%) 8 (12%) 5 (7%) n/a n/a
Myxofibrosarcoma 38 (28%) 18 (27%) 20 (29%) 0.06 0.05
Synovial Sarcoma 18 (13%) 9 (13%) 9 (13%) 0.01 0.08
UPS 10 (7%) 3 (4%) 7 (10%) n/a n/a
Spindle cell sarcoma 5 (4%) 1 (1%) 4 (6%) n/a n/a
Liposarcoma 6 (4%) 2 (3%) 4 (6%) n/a n/a
Other 39 (29%) 22 (33%) 17 (25%) 0.17 0.06
Size of Primary Tumour 133 (2%) 10.0 [6.0e13.3] 10.0 [6.0e13.2] 9.5 [5.5e14.0] 0.480 0.19 0.13
Grade of Primary Tumour
G1 132 (2.2%) 2 (2%) 0 (0%) 2 (3%) 0.407 n/a n/a
G2 23 (17%) 13 (19%) 10 (15%) 0.11 0.04
G3 107 (81%) 54 (81%) 53 (82%) 0.02 0.00
Surgery Primary Tumour
Limb Salvage 105 (22%) 90 (86%) 41 (79%) 49 (92%) 0.055 0.39 0.04
Amputation 15 (14%) 11 (21%) 4 (8%)
Adjuvant Therapy
No Adjuvant Therapy 96 (29%) 25 (26%) 16 (33%) 9 (19%) 0.356 0.31 0.06
(Neo-)Adjuvant RTX 61 (64%) 27 (55%) 34 (72%) 0.36 0.08
(Neo-)Adjuvant CTX 3 (3%) 2 (4%) 1 (2%) n/a n/a
Both 7 (7%) 4 (8%) 3 (6%) n/a n/a
Count of Metastases
Singular 135 (0%) 51 (38%) 15 (22%) 36 (53%) <0.0001 0.66 0.15
Multiple 84 (62%) 52 (48%) 32 (47%)
Number of Metastases* 135 (0%) 2 [1e9] 6 [2e9] 1 [1e3] <0.0001 0.96 0.20
Age at Metastasis (Years) 135 (0%) 65 [50e75] 67 [52e78] 63 [47e74] 0.158 0.25 0.07
Time to 1st Metastasis (Months) 134 (0.7%) 11 [4e20] 7 [3e20] 14 [6e25] 0.020 0.11 0.02
Location of Metastasis**
Lungs 134 (0.7%) 99 (74%) 56 (85%) 43 (63%) 0.039 0.50 0.15
Soft tissues þ LN 21 (16%) 4 (6%) 17 (25%) 0.54 0.17
Bone 7 (5%) 3 (5%) 4 (6%) n/a n/a
Organs 2 (1%) 1 (1.5%) 1 (1%) n/a n/a
Skip lesion 5 (4%) 2 (3%) 3 (4%) n/a n/a
Haemoglobin (g/dL) 98 (27%) 12.9 [11.0e14.3] 12.6 [10.6e13.3] 13.5 [11.5e14.8] 0.006 0.57 0.22
Albumin (g/dL) 61 (55%) 4.2 [3.5e4.6] 4.0 [3.2e4.2] 4.5 [4.0e4.8] 0.002 0.81 0.35
ECOG PS 103 (24%) 1 [0e1] 1 [0e2] 0.5 [0e1] 0.019 0.54 0.27
Summary estimates represent medians [25the75th percentile] for continuous variables, and absolute frequencies (%) for count data; P-values are from c2-tests, Fisher's exact
tests, and rank-sum tests; SMDs  0.3 were considered indicative of a potential covariate imbalance between the two treatment groups; p-values in bold are statistically
significant; *Number of metastases was truncated at 9 metastases in case of “innumerable” metastases according to radiology report; **In case of multiple metastastic sites,
this variables refers to the location of the clinically predominant metastatic site; Abbreviations: n (% missing) e Number of patients with available data for the respective
variable (% of patients with missing data), SMD e Standardized mean difference, SMD-IPTW e SMD after weighting of the data with the Inverse-Probability-of-Treatment-
Weight (IPTW), n/a e not applicable (SMDs were only calculated for rows that included at least 15 patients), MPNST e Malignant Peripheral Nerve Sheath Tumour, UPS e
Undifferentiated Pleomorphic Sarcoma, RTX e Radiotherapy, CTX e Chemotherapy, LN e Lymph nodes, ECOG PS e Eastern Cooperative Oncology Group Performance Status.
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dependent variable in this main analysis to account for poten-
tial immortal time bias due to the time between metastasis
diagnosis and metastasectomy [36e38]. Key prognostic variables
and variables which did not achieve an SMD < 0.3 after IPTW-
weighting were subsequently included in this Cox model to ac-
count for potential residual confounding. In a sensitivity analysis,
we used a “truncated” IPTW excluding patients with an IPTW <5%
or >95% of the IPTW's distribution [30]. To study potential pre-
dictive biomarkers for benefit from surgical intervention, we
fitted interactions between treatment assignment and several
clinical and laboratory markers. Due to the low power of inter-
action tests and the moderately large sample size, a p  0.1 was
considered to indicate statistical significance for this interaction
analysis. To further control for potential immortal time bias due
to the time between metastasis diagnosis and metastasectomy,
we finally performed landmark analyses with the landmark set atPlease cite this article in press as: Smolle MA, et al., Surgery for metach
analysis using propensity score methods, European Journal of Surgical O3 and 6 months after diagnosis of metastases [36e39]. The full
analysis code is available on request from FP.
Results
Baseline characteristics
The median age of the cohort at diagnosis of metachronous
metastases was 65 years [25the75th percentile: 50e75], and 55
patients (41%) were female. Further patient characteristics are
found in Table 1.
On average, patients developed metastatic disease after a me-
dian follow-up of 11 months (IQR: 4e20 months). Ninety-nine
patients first presented with lung metastases (73%), 21 with me-
tastases to soft tissues and lymph nodes (16%) and 7 patients with
metastases to bone (5%). Furthermore, 5 patients had skip lesions
(4%) and 2 patients presented with intestinal metastases (1%).ronous metastasis of soft tissue sarcoma e A magnitude of benefit
ncology (2018), https://doi.org/10.1016/j.ejso.2018.06.019
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(1%). Fifty-one patients had one metastatic lesion only (38%) while
84 patients presented with multiple metastases (62%). Fifty-nine
patients developed further metastases after diagnosis of the first
metastasis (44%).
Of the 99 patients with primary metastases to the lungs, 28
presented with a singular pulmonary nodule (28%) and 71 with
multiple lesions (72%). Forty-seven patients had pulmonary nod-
ules restricted to one side (48%) and 51 patients had metastatic
lesions in both lungs (52%). In one patient, the involvement of the
other side was uncertain.
Altogether, 67 patients (50%) were not treated surgically, of
whom 32 received best supportive care (BSC) and 35 were
administered CTX ± RTX. The remaining 68 patients underwent
surgery (50%, Supplementary Table 2). Surgical interventions in the
metastatic setting included wedge-resections (n ¼ 16, 23%) and
lobectomies (n ¼ 28, 41%) of lung metastases, as well as (lymph
node) extirpations (n ¼ 10, 15%) and resections (n ¼ 14, 21%) for
peripheral metastases.
As expected, patients in the surgical group had a significantly
higher baseline prevalence of favourable prognostic factors as
compared to patients in the non-surgery group. For example,
patients who underwent surgery had less metastatic lesions
(median: 1 vs. 6 [SMD ¼ 0.96]), a better ECOG performance status
(median: 0.5 vs. 1 [SMD ¼ 0.54]), and higher haemoglobin levels
(median: 13.5 vs. 12.6 g/dL [SMD ¼ 0.57], Table 1).
After the diagnosis of metachronous metastases, patients were
followed up for a median interval of 4.9 years (range: 1 daye16.6
years). Seventy-five percent and 25% of the cohort were followed
up for at least 1.9 years and 9.3 years, respectively. During follow-
up we observed 89 deaths (66%), corresponding to 1-, 5-, and 10-
year OS estimates of 63%, 24%, and 15% (Supplementary Figure 2).
Seventy-three (82%) of these 89 deaths were due to disease pro-
gression, five deaths (6%) were due to other causes, while cause of
death was unknown in 11 cases (12%). Prognostic factors for OS in
the univariate setting are reported in Table 2. The strongest uni-
variable predictors of worse OS were higher ECOG performance
status, upper limb tumour location, a higher number of metastases,
the presence of brainmetastases, anaemia, and hypoalbuminaemia,
respectively.Table 2
Univariable Analysis of Prognostic Factors for Overall Survival (OS).
Variable
Female gender
Age at metastasis (per 5 years increase)







Number of metastases* (per 1 metastasis increase)
Time to 1st metastasis (per 5 months increase**)
Metastasis location
Any lung metastasis
Any soft tissue and/or lymph node metastasis
Any bone metastasis
Any solid organ metastasis (excluding lung and brain)
Any brain metastasis
Limb amputation upon primary surgery
Haemoglobin (per 1 g/dL increase)
Albumin (per 1 g/dL increase)
Estimates were obtained with univariable Cox proportional hazards models in multi
tastases was truncated at 9 metastases in case of “innumerable”metastases according
for calculation of the “time to 1st metastasis” variable. Abbreviations: HR e Hazard
Cooperative Oncology Group.
Please cite this article in press as: Smolle MA, et al., Surgery for metach
analysis using propensity score methods, European Journal of Surgical OSurgery and OS in metachronous metastases of STS
In the unadjusted analysis, OS was significantly longer in those
68 patients who had undergone surgical interventions compared to
the 67 patients who had not (Fig. 1). One-, 5-, and 10-year OS-
estimates were 83%, 34% and 23% in the surgery group, and 38%,
11% and 4% in the non-surgery group, respectively (log-rank-
p<0.0001). Median OS was 2.7 years since diagnosis of first
metastasis (95% CI: 1.6e3.9) in the surgery group, and 0.8 years
(95% CI: 0.4e1.2) in the non-surgery group, respectively.
To account for the significantly higher prevalence of favourable
prognostic factors in the surgery group (consistent with a non-
random assignment to the two treatment groups), we predicted a
propensity score and an inverse-probability-of-treatment-weight
(IPTW, see Supplementary Table 1 and Supplementary Fig. 3A, B).
Re-weighting of the data removed nearly all imbalances in key
prognostic variables between the two groups, except for albumin
(Table 1). For example, the SMD for the number of metastatic le-
sions was reduced from 0.96 to 0.20, for ECOG performance status
from 0.54 to 0.27, and for haemoglobin from 0.57 to 0.22,
respectively.
The favourable association between any surgical intervention
and lower risk of death prevailed after re-weighting the data for the
IPTW. In detail, the IPTW-weighted 1-, 5-, and 10-year OS-
estimates were 86%, 31% and 17% in the surgery group, and 39%,
10% and 3% in the non-surgery group, respectively (log-rank-
p<0.0001, Fig. 2). The corresponding IPTW-adjusted median OS
estimates were 3.3 years and 0.9 years in the surgery and non-
surgery group, respectively. Further multivariable adjustment for
other relevant predictors of worse OS, such as poor ECOG
performance status, higher number of metastases, low
haemoglobin and low albumin did not alter this association
(adjusted HR for metastasectomy treated as a time-dependent
variable ¼ 0.55, 0.30e0.98, Table 3).
Exploration of potential predictive factors for benefit from
metastasectomy
We fitted interactions between treatment assignment and



















ply-imputed data. p-values in bold are statistically significant; *Number of me-
to radiology report; ** The date of primary surgery was used as the baseline date
ratio, 95% CI e 95% confidence interval, p e Wald-test p-value, ECOG e Eastern





















68 32(28) 16(10) 10(2) 7(1) 3(1)No Surgery
67 8(42) 4(2) 1(3) 1(0) 1(0)Surgery
Number at risk
0 2 4 6 8 10
Time after metastasis diagnosis (years)
Surgery (n=68) No Surgery (n=67)
(Deaths)
Fig. 1. Crude Kaplan-Meier Overall Survival (OS) functions by treatment group for
metastasis. Numbers in round brackets in the risk table report the number of deaths in
the respective time interval.
Table 3
Multivariable IPTW-weighted analysis of Overall Survival (OS).
Variable HR 95% CI p-value
Multivariable Cox regression Model
Metastasectomy as a time-dependent covariate 0.55 0.30e0.98 0.043
ECOG performance status (per 1 point increase) 1.72 1.22e2.42 0.002
Number of metastases* (per 1 metastasis increase) 0.99 0.91e1.07 0.730
Haemoglobin (per 1 g/dL increase) 1.00 0.83e1.20 0.984
Albumin (per 1 g/dL increase) 0.81 0.39e1.65 0.541
Multivariable Model#1 is a multivariable Cox model, which was weighted with the
Inverse-Probability-of-Treatment-Weight (IPTW). Multivariable Model #2 is also an
IPTW-weighted multivariable Cox Model. with, metastasectomy was treated as a
time-dependent covariate Both models were estimated from multiply-imputed
data. p-values in bold are statistically significant; *Number of metastases was
truncated at 9 metastases in case of “innumerable” metastases according to radi-
ology report. Abbreviations: HR e Hazard ratio, 95% CI e 95% confidence interval, p
e Wald-test p-value, ECOG e Eastern Cooperative Oncology Group.
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surgical intervention (Table 4). In this analysis of predictive
markers, the potential benefit of surgical intervention was
consistent across important clinical subgroups such as patients
(1) with and without poor ECOG performance status, (2) a
metachronous interval of  or < 12 months or (3) an age  or
<70 years at metastasis diagnosis. Importantly, with the modi-
fied threshold of statistical significance of p < 0.1 for this inter-
action analysis, the benefit of metastasectomy was stronger in
patients with a single metastasis (HR ¼ 0.21) than in patients
with multiple metastases (HR ¼ 0.44, p for interaction ¼ 0.096).
Although not statistically significant, the regression coefficients
at least pointed in the direction of metastasectomy being slightly
more efficacious in patients with a metachronous interval of at
least 12 months.Landmark analysis
The median time between metastasis diagnosis and meta-
stasectomy was 1.7 months [IQR: 0.7e3.6]. In previous analyses,
this potential immortal time bias was controlled for by treating



















0 2 4 6 8 10
Time after metastasis diagnosis (years)
Surgery (n=68) No Surgery (n=67)
Fig. 2. Inverse-probability-of-treatment-weighted (IPTW) Kaplan-Meier Overall
Survival (OS) functions by treatment group. No risk table is displayed because the
numbers of patients at specific time points are non-integers in an IPTW-weighted
sample.
Please cite this article in press as: Smolle MA, et al., Surgery for metach
analysis using propensity score methods, European Journal of Surgical Oanalysis of immortal time bias, we performed IPTW-eweighted
landmark analyses with landmarks at 3 and 6 months after
metastasis diagnosis, respectively. With a landmark at 3 months,
the 5-year OS estimates were 27.8% and 14.5% in the surgery and
non-surgery group, respectively (Fig. 3A), and similar results were
observed for a landmark at 6 months (Fig. 3B).Discussion
Previous non-controlled observational studies have reported
very favourable survival outcomes in patients with metastatic STS
who underwent metastasectomy [6e23]. However, whether these
encouraging results are attributable to metastasectomy or simply
due to selection bias has so far not been adequately proven
[25e27]. Aiming to fill this gap of evidence, we performed a
comparative effectiveness analysis of surgery versus non-surgery
for patients with metachronous metastasis of STS. Using
propensity score methods, landmark analysis, and time-
dependent Cox modelling to control for selection and immortal
time bias, we observed that metastasectomy was associated with
prolonged overall survival. In the absence of randomisation, these
data support the hypothesis that surgery may improve survival of
patients with metachronous metastases of STS.
An important aspect of STS-management is the therapeutic
approach in the metastatic setting. Depending on the patients'
general condition, site of metastases and overall tumour load, non-
surgical interventions (i.e. BSC, CTX, RTX) or a surgical approach
may be chosen [40,41]. In our cohort, half of the patients under-
went a surgical intervention for their metastases, about one quarter
received RTX ± CTX and another quarter received BSC. Consistent
with the literature, the most common location of primary metas-
tasis in our cohort was the lung, followed by soft tissues and lymph
nodes [6,34,42,43].
In the univariate setting, patients undergoing surgical in-
terventions had significantly better 5- and 10-year survival of 34%
and 23% vs. 11% and 4% for the non-surgery group
(BSC ± RTX ± CTX), respectively. These data are in line with the
observations made by Billingsley et al. in a large retrospective
cohort of STS-patients with pulmonary metastases [6].
Given the retrospective design of this study and the non-
controlled design of many studies performed in the past
[6e23,33,34,44,45], one may argue that the benefit of surgical
intervention can be explained by favourable clinical parameters
prevailing in the surgical-group. Indeed, patients undergoing sur-
gical resection in our cohort presented with fewer metastases and a
longer interval between initial surgery and occurrence of metas-
tasis, and also had a better ECOG performance status and higher
haemoglobin level at the time of treatment decision. These featuresronous metastasis of soft tissue sarcoma e A magnitude of benefit
ncology (2018), https://doi.org/10.1016/j.ejso.2018.06.019
Table 4
Predictive factors for overall survival (OS) benefit from metastasectomy e Interaction analysis.
Hazard ratio 95% CI Interaction p-value
ECOG performance status: 0 points 0.43 0.18e1.02 0.373
ECOG performance status: 1e2 points 0.27 0.13e0.42
Time between primary surgery and metastasis onset <12 months 0.49 0.21e0.78 0.154
Time between primary surgery and metastasis onset 12 months 0.27 0.14e0.50
Age < 70 years 0.36 0.21e0.62 0.678
Age  70 years 0.30 0.15e0.59
Number of metastases: Single 0.21 0.10e0.43 0.096
Number of metastases: Multiple 0.44 0.26e0.77
All estimates were obtained from IPTW-weighted Cox models after multiple imputations of missing data. Hazard ratios are for metastasectomy versus non-invasive management.
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Fig. 3. Landmark analysis of estimated Overall Survival (OS) by treatment group. Survivor functions were predicted from univariable Cox models. Panel A: Landmark point
(short-dashed blue vertical line) set at 3 months after metastasis diagnosis. Panel B: Landmark point set at 6 months after metastasis diagnosis.
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survival of STS-patients with metastatic disease [4,33,34].
Therefore, we used a propensity score approach with IPTW-
weighting to compensate for differences at treatment decision
between patients undergoing surgical interventions and those who
did not. After weighting all patients for the IPTW-score and re-
calculating the uni- and multivariable time-to-death analyses, any
surgical intervention remained a significant positive prognostic
factor for post-metastasis-survival independent of ECOG perfor-
mance status, number of metastases, haemoglobin- and albumin-
levels. The magnitude of association of surgery with OS was large,
suggesting that patients with metachronous metastases from STS
may gain more than two years in median OS frommetastasectomy.
The potential benefit of surgery even prevailed in the landmark and
time-dependent Cox regression analyses in which immortal time
bias due to time between metastasis diagnosis and surgery was
accounted for.
By fitting interactions between clinically relevant baseline
covariates and treatment assignment, we aimed to identify pre-
dictive markers of benefit from surgery. This analysis suggested
that the benefit of surgery was greater for patients with singular
metastasis at the time of surgery, but was otherwise consistent
across several clinically-meaningful subgroups.
Our study is not without limitations. Due to its retrospective
design, the study depends on the quality and availability of medical
records, pathology reports and medical images. Moreover, the
validity of the IPTW analysis depends on the difficult-to-testPlease cite this article in press as: Smolle MA, et al., Surgery for metach
analysis using propensity score methods, European Journal of Surgical Oassumption that the propensity score model is correctly specified
[35]. Furthermore, other hidden confounding factors, such as
comorbidities not covered by the ECOG performance status, could
not be considered in the calculations. Otherwise, a major strength
of our analysis is that all study patients were drawn from estab-
lished cohorts at Graz and Leiden that included all consecutive
patients who had previously undergone resection with curative
intent for localised STS. With this approach, we could reduce se-
lection bias in both surgery and non-surgery groups.
Conclusion
This comparative effectiveness analysis of observational data
using propensity score methods supports the hypothesis that sur-
gery may be an efficacious treatment option for metachronous
metastases of STS with a potentially sizeable benefit in terms of
improving overall survival. Moreover, the potential benefit of sur-
gical intervention appears to be consistent across clinically
important subgroups, although surgery may be less efficacious in
patients with multiple metastases. These data should be taken into
account by clinicians treating sarcomas and their patients when
planning treatment for metachronous metastases of STS.
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